Irvine, California, March 16, 2026
mdxhealth SA announced new clinical data from the ProMPT study led by the University of Oxford, demonstrating that its Genomic Prostate Score (GPS mdx) test can effectively predict adverse outcomes across multiple treatment strategies in prostate cancer patients. The findings were presented at the European Association of Urology (EAU) Congress 2026 in London, highlighting the growing role of genomic diagnostics in precision oncology and personalized treatment decision-making.
Genomic Insights Enable Personalized Prostate Cancer Care
The GPS mdx test, a 17-gene expression assay, is designed to provide personalized genomic insights into tumor biology, helping clinicians assess the risk of disease progression and tailor treatment strategies accordingly. In the ProMPT study, involving 409 patients with localized or locally advanced prostate cancer and a median follow-up of six years, the test demonstrated its ability to identify patients with biologically indolent tumors, even among those classified as clinically higher risk.
This capability enables treatment de-escalation, allowing patients to avoid unnecessary aggressive interventions while maintaining favorable outcomes. The study reinforces the importance of precision diagnostics in improving clinical decision-making and reducing overtreatment in oncology.
Strong Clinical Outcomes Across Multiple Treatment Pathways
Advertisement
The ProMPT study evaluated patients undergoing active surveillance, radical prostatectomy, and radiotherapy, providing a comprehensive assessment of the test’s predictive performance across different treatment pathways. The results showed excellent six-year freedom-from-failure outcomes, including 92% in active surveillance patients and up to 100% in patients treated with surgery or radiotherapy.
These outcomes were comparable to those observed in clinically low-risk patient groups, demonstrating the test’s ability to accurately stratify risk and guide treatment selection. By integrating genomic data with traditional clinical and pathological factors, the GPS mdx test offers a more holistic understanding of disease behavior, supporting improved patient management and long-term outcomes.
Advancing Precision Diagnostics Through Clinical Evidence
The study represents a significant milestone in mdxhealth’s collaboration with the University of Oxford and contributes to the ongoing GPS-ProtecT study, which aims to establish the GPS mdx test as the first genomic classifier supported by randomized clinical trial evidence in prostate cancer management. The broader ProtecT trial, involving more than 1,500 patients followed over two decades, provides one of the most comprehensive datasets for evaluating long-term treatment effectiveness.
The integration of genomic testing into such large-scale clinical research underscores the growing importance of molecular diagnostics in transforming cancer care, enabling clinicians to make data-driven, personalized treatment decisions. As healthcare continues to shift toward precision medicine, tools like the GPS mdx test are expected to play a critical role in improving outcomes and optimizing resource utilization across healthcare systems.
Source: mdxhealth press release
